Study targets men whose cancers stopped responding to hormone therapy Men taking the drug enzalutamide had delayed cancer re-appearance of almost two years Men taking enzalutamide had a 71 percent lower risk of metastasis or death than placebo Drug already FDA-approved for advanced prostate cancer
CHICAGO — Men with non-metastatic castrate-resistant prostate cancer and a quickly rising PSA level present a medical dilemma. The rising PSA (prostate-specific antigen) means there is cancer activity, but no visible metastasis in a scan.
These men are receiving hormone treatments to reduce the testosterone on which their cancer feeds, but their cancers have become resistant to that treatment. Until recently, there has not been an effective treatment to improve their outcome.
Now there might be one, reports a new study by a Northwestern Medicine clinical researcher. The double-blind, randomized phase III trial shows a drug currently used to treat men with metastatic, advanced prostate cancer significantly lowered the risk of metastasis or death when used in men with non-metastatic castrate-resistant prostate cancer and a rising PSA level.
Men who took the drug, enzalutamide, had a 71 percent lower risk of metastasis or death than those who took the placebo
Article originally posted at